UMGCC requests developmental funds amounting to $260,000, or 9 percent of the total direct costs of its budget. These funds are essential for UMGCC to: ? Pilot projects for Developing Pain Studies Program ($50,000) ? Provide funds to support the establishment of three new developing shared sen/ices ($60,000) ? Fund five new pilot projects for Shared Services annually ($50,000) ? Conduct recruiting for epidemiology ($100,000) Developmental funds will be necessary for UMGCC's leadership to recruit faculty in high-priority areas established by the strategic planning process. In addition, the promotion of Interdisciplinary research will require seed money for pilot grant support in areas that bring investigators of different disciplines together and utilize UMGCC's shared services. Finally, core grant support will be necessary for further establishing essential shared services, such as imaging, molecular pathology, and high-throughput screening. Developmental funds from the P30 Grant will continue to be leveraged by additional funds from Maryland's CRFP and the American Cancer Society (ACS) over the next 5 years. Allocation of developmental funds will be through (a) the strategic-planning process internal to UMGCC, with peer review and approval of the UMGCC Research Council;and (b) recruitment in predefined areas that meet the criteria established by senior leadership. The 2008 NCI Site Visit Report gave this section an Excellent to Very Good rating. NCI thought that requests were well justified and the monies would augment the substantial investment that UMGCC had made in developing programs and shared services. NCI noted the description of the planned usage of these combined investments lacked adequate focus and prioritization of two developing programs and four additional shared services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA134274-07
Application #
8711297
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
7
Fiscal Year
2014
Total Cost
$121,771
Indirect Cost
$29,723
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Appelt, Ane L; Vogelius, Ivan R; Pløen, John et al. (2014) Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys 90:110-8
Vogelius, Ivan R; Bentzen, Søren M (2014) Hypofractionated radiation therapy for prostate cancer: more food for thought from recent trial. J Clin Oncol 32:1852-3
Bao, Ting; Cai, Ling; Snyder, Claire et al. (2014) Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 120:381-9
Barnett, Gillian C; Thompson, Deborah; Fachal, Laura et al. (2014) A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol 111:178-85
Bentzen, S M; Yarnold, J (2014) A toast to the silver anniversary of Clinical Oncology: a quarter of a century of advances in evidence-based radiation dose fractionation. Clin Oncol (R Coll Radiol) 26:599-601
Håkansson, Katrin; Specht, Lena; Aznar, Marianne C et al. (2014) Prescribing and evaluating target dose in dose-painting treatment plans. Acta Oncol 53:1251-6
Due, Anne K; Vogelius, Ivan R; Aznar, Marianne C et al. (2014) Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 111:360-5
Song, Xiaomeng; Xia, Ronghui; Li, Jiang et al. (2014) Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin Cancer Res 20:701-10
Gojo, Ivana; Tan, Ming; Fang, Hong-Bin et al. (2013) Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 19:1838-51
Natarajan, Karthika; Xie, Yingqiu; Burcu, Mehmet et al. (2013) Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One 8:e74653

Showing the most recent 10 out of 18 publications